Semarion is a seed-stage spin-out from Cambridge University with a mission to accelerate the pace of drug discovery. We are revolutionising adherent cell screening to produce better drug data, faster. Our proprietary SemaCyte® microcarrier platform leverages novel materials physics to introduce flexibility, miniaturisation, and multiplexing into existing drug discovery workflows. By deploying techniques from the microchip industry, we create magnetically steerable cell carrier systems which can move small colonies of adherent cells for accelerated drug discovery and completely novel research paradigms.

Stay up to date with Semarion

Login or create a free user account to follow this company and see updates on your dashboard.

Create account